Skip to main content

Advertisement

SpringerLink
Log in

Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

In vitro studies have implicated neuroendocrine differentiation in the development of hormone resistant prostate cancer following administration of androgen blockers. Studies on clinical material are equivocal. We wished to understand the significance of neuroendocrine differentiation in our large and well-characterised cohort of clinically localised prostate cancer, treated conservatively. Immunohistochemical expression of chromogranin-A was assessed semi-quantitatively on tissue samples of 806 patients in a tissue microarray approach. The correlation of expression with 10-year prostate cancer survival was examined. Multivariate analysis including contemporary Gleason score was performed and sub-group analysis of early hormone treated patients was also undertaken. Chromogranin-A expression correlated with high Gleason score (χ 2 = 28.35, p < 0.001) and early prostate cancer death (HR = 1.61, 95 %CI = 1.15–2.27, p < 0.001). In univariate analysis, NE differentiation correlated significantly with outcome (HR = 1.61, 95 % CI 1.15-2.27, p < 0.001) However in multivariate analysis including Gleason score, chromogranin-A expression was not an independent predictor of survival (HR = 0.97, 95 %CI = 0.89–1.37, p = 0.87). Although chromogranin-A expression was higher in patients with early hormone therapy (χ 2 = 7.25, p = 0.007), there was no association with prostate cancer survival in this sub-group (p = 0.083). Determination of neuroendocrine differentiation does not appear to have any bearing on the outcome of prostatic carcinoma and does not add to the established prognostic model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bonkhoff H, Stein U, Remberger K (1993) Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 423:291–294

    Article  PubMed  CAS  Google Scholar 

  2. Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, Schroder FH, van der Kwast TH (1993) Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 100:393–398

    Article  PubMed  CAS  Google Scholar 

  3. Ather MH, Abbas F, Faruqui N, Israr M, Pervez S (2008) Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol 8:21

    Article  PubMed  Google Scholar 

  4. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H (2002) Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 167:512–515

    Article  PubMed  CAS  Google Scholar 

  5. Di Sant' Agnese PA (1992) Neuroendocr Differ Carcinoma Prostate Cancer 70:254–268

    Google Scholar 

  6. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101

    Article  PubMed  CAS  Google Scholar 

  7. Yokomizo A, Murai M, Baba S, Ogawa O, Tsukamoto T, Niwakawa M, Tobisu K, Kinukawa N, Naito S (2006) Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. BJU Int 98:549–553

    Article  PubMed  CAS  Google Scholar 

  8. Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Moller H, Reuter V, Fearn P, Eastham J, Scardino P (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95:1186–1194

    Article  PubMed  CAS  Google Scholar 

  9. Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, Demers R, Menon M (2004) Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 171:1513–1519

    Article  PubMed  Google Scholar 

  10. Cox ME, Deeble PD, Lakhani S, Parsons SJ (1999) Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 59:3821–3830

    PubMed  CAS  Google Scholar 

  11. Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, Hu CD (2008) Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res 68:9663–9670

    Article  PubMed  CAS  Google Scholar 

  12. Diaz M, Abdul M, Hoosein N (1998) Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2. Prostate Suppl 8:32–36

    Article  PubMed  CAS  Google Scholar 

  13. Huss WJ, Gregory CW, Smith GJ (2004) Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate 60:91–97

    Article  PubMed  Google Scholar 

  14. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ (2002) Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 50:203–215

    Article  PubMed  CAS  Google Scholar 

  15. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr, Evans CP (2007) Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis 10:6–14

    Article  PubMed  CAS  Google Scholar 

  16. Quiros-Gonzalez I, Sainz RM, Hevia D, Mayo JC MnSOD drives neuroendocrine differentiation, androgen independence, and cell survival in prostate cancer cells. Free Radic Biol Med 50:525–536

  17. Wu C, Huang J (2007) Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 282:3571–3583

    Article  PubMed  CAS  Google Scholar 

  18. Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF (2003) Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene 22:6704–6716

    Article  PubMed  CAS  Google Scholar 

  19. Abrahamsson PA, Cockett AT, di Sant'Agnese PA (1998) Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate Suppl 8:37–42

    Article  PubMed  CAS  Google Scholar 

  20. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG, van der Kwast TH (1997) The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 158:171–174

    Article  PubMed  CAS  Google Scholar 

  21. Autorino R, Di Lorenzo G, D'Armiento FP, Mignogna C, Cindolo L, De Sio M, Perdona S, De Fortuna E, Salzano L, De Placido S, D'Armiento M (2005) Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer. Minerva Urol Nefrol 57:319–324

    PubMed  CAS  Google Scholar 

  22. Sciarra A, Mariotti G, Gentile V, Voria G, Pastore A, Monti S, Di Silverio F (2003) Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU Int 91:438–445

    Article  PubMed  CAS  Google Scholar 

  23. Kadmon D, Thompson TC, Lynch GR, Scardino PT (1991) Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 146:358–361

    PubMed  CAS  Google Scholar 

  24. Gunia S, Albrecht K, Koch S, Herrmann T, Ecke T, Loy V, Linke J, Siegsmund M, May M (2008) Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 26:243–250

    Article  PubMed  Google Scholar 

  25. Berney DM, Fisher G, Kattan MW, Oliver RT, Moller H, Fearn P, Eastham J, Scardino P, Cuzick J, Reuter VE, Foster CS (2007) Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int 100:1240–1244

    Article  PubMed  Google Scholar 

  26. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228–1242

    Article  PubMed  Google Scholar 

  27. Turbat-Herrera EA, Herrera GA, Gore I, Lott RL, Grizzle WE, Bonnin JM (1988) Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study. Arch Pathol Lab Med 112:1100–1105

    PubMed  CAS  Google Scholar 

  28. Bonkhoff H (2001) Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 12(Suppl 2):S141–S144

    Article  PubMed  Google Scholar 

  29. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY (2001) Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 48:7–15

    Article  PubMed  CAS  Google Scholar 

  30. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ (2000) Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 60:741–748

    PubMed  CAS  Google Scholar 

  31. Allen FJ, Van Velden DJ, Heyns CF (1995) Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? Br J Urol 75:751–754

    Article  PubMed  CAS  Google Scholar 

  32. Tan MO, Karaoglan U, Celik B, Ataoglu O, Biri H, Bozkirli I (1999) Prostate cancer and neuroendocrine differentiation. Int Urol Nephrol 31:75–82

    Article  PubMed  CAS  Google Scholar 

  33. Cerovic SJ, Brajuskovic GR, Vukotic Maletic VD, Micic SR (2004) Neuroendocrine differentiation in prostate cancer. Vojnosanit Pregl 61:513–518

    Article  PubMed  Google Scholar 

  34. Cindolo L, Cantile M, Franco R, Chiodini P, Schiavo G, Forte I, Zlobec I, Salzano L, Botti G, Gidaro S, Terracciano L, Cillo C Parallel determination of neuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers. Int Braz J Urol 37:57–66

  35. Falkmer S, Askensten U, Grimelius L, Abrahamsson PA (1990) Cytochemical markers and DNA content of neuroendocrine cells in carcinoma of the prostate gland during tumour progression. Acta Histochem Suppl 38:127–132

    PubMed  CAS  Google Scholar 

  36. Cohen RJ, Glezerson G, Haffejee Z (1991) Neuro-endocrine cells—a new prognostic parameter in prostate cancer. Br J Urol 68:258–262

    Article  PubMed  CAS  Google Scholar 

  37. Collado B, Gutierrez-Canas I, Rodriguez-Henche N, Prieto JC, Carmena MJ (2004) Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul Pept 119:69–75

    Article  PubMed  CAS  Google Scholar 

  38. Humez S, Monet M, Legrand G, Lepage G, Delcourt P, Prevarskaya N (2006) Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr Relat Cancer 13:181–195

    Article  PubMed  CAS  Google Scholar 

  39. di Sant'Agnese PA (2001) Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 12(Suppl 2):S135–S140

    Article  PubMed  Google Scholar 

  40. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA (2000) Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 42:274–279

    Article  PubMed  CAS  Google Scholar 

  41. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N (2004) Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45:586–592, discussion 592

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure of conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Molecular Oncology, Barts Cancer Institute, Charterhouse Square, London, EC1M 6BQ, UK

    S. S. Jeetle, E. Stankiewicz & D. M. Berney

  2. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, UK

    G. Fisher, Z. H. Yang & J. Cuzick

  3. Thames Cancer Registry, Kings College London, London, UK

    H. Møller

  4. Male Urological Cancer Research Centre, Institute of Cancer Research, Surrey, UK

    C. S. Cooper

Authors
  1. S. S. Jeetle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z. H. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Stankiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Møller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. S. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Cuzick
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. M. Berney
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of The Trans-Atlantic Prostate Group

Corresponding author

Correspondence to D. M. Berney.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jeetle, S.S., Fisher, G., Yang, Z.H. et al. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. Virchows Arch 461, 103–107 (2012). https://doi.org/10.1007/s00428-012-1259-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-012-1259-2

Keywords

Search

Navigation